Phibro Animal Health (NASDAQ:PAHC) Upgraded to “Strong-Buy” at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Thursday.

A number of other equities research analysts have also recently weighed in on PAHC. Barclays lifted their price objective on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. JPMorgan Chase & Co. started coverage on Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. Finally, Bank of America lifted their target price on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a report on Friday, August 30th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Phibro Animal Health currently has an average rating of “Hold” and a consensus price target of $16.50.

Phibro Animal Health Stock Performance

PAHC stock opened at $23.59 on Thursday. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. The stock has a market capitalization of $955.40 million, a price-to-earnings ratio of 54.86, a PEG ratio of 0.62 and a beta of 0.51. Phibro Animal Health has a 1 year low of $9.49 and a 1 year high of $25.98. The stock’s fifty day moving average is $23.27 and its two-hundred day moving average is $20.14.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. The business had revenue of $273.16 million for the quarter, compared to analysts’ expectations of $262.44 million. On average, research analysts predict that Phibro Animal Health will post 1.61 EPS for the current year.

Insider Buying and Selling

In other Phibro Animal Health news, Director E Thomas Corcoran acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was purchased at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the transaction, the director now owns 25,000 shares of the company’s stock, valued at $500,500. The trade was a 25.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 50.07% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently bought and sold shares of PAHC. Sofinnova Investments Inc. acquired a new stake in Phibro Animal Health during the 2nd quarter worth about $3,975,000. American Century Companies Inc. lifted its holdings in shares of Phibro Animal Health by 119.6% during the 2nd quarter. American Century Companies Inc. now owns 347,191 shares of the company’s stock valued at $5,822,000 after buying an additional 189,068 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Phibro Animal Health by 116.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company’s stock valued at $4,330,000 after buying an additional 103,491 shares during the last quarter. Dana Investment Advisors Inc. lifted its holdings in shares of Phibro Animal Health by 17.2% during the 2nd quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after buying an additional 75,546 shares during the last quarter. Finally, Algert Global LLC lifted its holdings in shares of Phibro Animal Health by 521.1% during the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company’s stock valued at $1,606,000 after buying an additional 59,850 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.